- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06254014
A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients
A Phase 3, Multi-center, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of JY09 in Patients With T2DM Inadequately Controlled by Diet and Exercise Alone
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study was designed as a multicenter, randomized, double-blind, placebo-parallel controlled Phase III clinical study to evaluate the efficacy and safety of Exendin-4Fc fusion protein (JY09) injection in adult subjects with type 2 diabetes mellitus (T2DM) who have poor glycemic control after dietary exercise intervention only.
The proposed plan is to enroll 270 subjects with T2DM, using stratified block group randomization, with the stratification factor being baseline HbA1c (≤8.5% or >8.5%), and randomly assign them to the 1.2 mg JY09 injection group (n=90 subjects), the 2.4 mg JY09 injection group (n=90 subjects), and the placebo group (n=90 subjects) in a 1:1:1 ratio.
The trial was divided into 4 phases, i.e., a screening period of 2 weeks, a single-blind introduction period of 4 weeks, a treatment period of 54 weeks (26 weeks for the core treatment period and 28 weeks for the extended treatment period), and a safety follow-up period of 4 weeks. Total 64 weeks.
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Xuefeng Li, Master
- Phone Number: 13683259746
- Email: lixuefeng@east-bt.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100044
- Peking University People's Hospital
-
Contact:
- Linong Ji, Doctor
- Phone Number: 010-88324105
- Email: jiln@bjmu.edu.cn
-
Sub-Investigator:
- Leili Gao, Doctor
-
Principal Investigator:
- Linong Ji, Doctor
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female subjects ≥18 years of age and ≤75 years of age at the time of signing the informed consent form.
- Those who met the diagnostic criteria for type 2 diabetes mellitus promulgated by World Health Organization(WHO) in 1999 and who had been diagnosed with T2DM for ≥12 weeks.
- Those who received dietary and exercise interventions for ≥8 weeks prior to screening and who had not received any antidiabetic medications in the 8 weeks prior to screening.
- HbA1c ≥7.5% and ≤11.0% at screening (local laboratory) and HbA1c ≥7.0% and ≤10.5% before randomization (V3) (central laboratory).
- FPG 13.9 mmol/L at screening (local laboratory) and FPG 13.9 mmol/L before randomization (V3) (central laboratory).
- Body mass index (BMI) ≥18.5 kg/m2 and ≤35.0 kg/m2 at screening and before randomization (V3).
- Able to understand and willing to sign a written informed consent form (ICF) and comply with the study protocol.
Exclusion Criteria:
- People diagnosed with type 1 diabetes or other types of diabetes.
- Those who have used other hypoglycemic agents within 8 weeks prior to screening or prior to randomization (V3), or those who have used medications that may affect glucose metabolism, such as systemic glucocorticoids (except for inhalation or topical topical use), growth hormones, etc.
- Acute complications of diabetes, such as diabetic ketoacidosis or hyperglycemic hyperosmolar state, within 6 months prior to screening or prior to randomization.
- Severe chronic complications of diabetes mellitus (e.g., proliferative diabetic retinopathy, severe diabetic neuropathy, diabetic foot, etc.) within 6 months prior to screening, which are assessed by the investigator to be unsuitable for participation in this clinical study.
- Persons who have had a severe trauma or serious infection within 1 month prior to screening or prior to randomization (V3) that may affect glycemic control, and persons who currently have a complicated or refractory urinary or genital tract infection.
- Suffering from any condition at screening or prior to randomization (V3) that may cause hemolysis or red blood cell instability that would interfere with the measurement of HbA1c levels, such as hemolytic anemia.
- Subjects who have abnormal thyroid function tests at Screening and require medication, or subjects who are being treated with thyroid-related medications whose thyroid function is still not well controlled at Screening.
- Those with any of the following abnormalities on serologic testing at screening:
1)Positive human immunodeficiency virus antibodies or syphilis spirochete-specific antibodies; 2)Hepatitis C antibody positive; 3)Hepatitis B virus surface antigen (HBsAg) positive and hepatitis B viral load (HBV-DNA) above the lower limit of laboratory testing (HBV-DNA is added only if HBsAg is positive); 9. The subject has other conditions that, in the judgment of the investigator, make participation in this clinical study inappropriate.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Exendin-4 Fc fusion protein injection(1.2mg)
1.2mg,Subcutaneous injection in the abdomen,Bi-weekly for 54 weeks.
|
1.2mg, subcutaneous injection in the abdomen, biweekly, 54 weeks of treatment.
Other Names:
The first dose of 1.2 mg was administered subcutaneously in the abdomen, and after two weeks, the dose was adjusted to 2.4 mg, followed by a continuation of treatment for 52 weeks.
Other Names:
|
Experimental: Exendin-4 Fc fusion protein injection(2.4mg)
The first dose of 1.2 mg of JY09 injection was administered, the dose was adjusted to 2.4 mg after two weeks, after which 2.4 mg was maintained to continue subcutaneous injection in the abdomen, bi-weekly treatment for 52 weeks.
|
1.2mg, subcutaneous injection in the abdomen, biweekly, 54 weeks of treatment.
Other Names:
The first dose of 1.2 mg was administered subcutaneously in the abdomen, and after two weeks, the dose was adjusted to 2.4 mg, followed by a continuation of treatment for 52 weeks.
Other Names:
|
Placebo Comparator: placebo(0.6ml)
JY09 placebo injection 0.6 ml, biweekly abdominal subcutaneous injection for 26 weeks, followed by randomization in a 1:1 ratio into JY09 (1.2 mg) and JY09 (2.4 mg) for 28 weeks, biweekly subcutaneous injections.
|
0.6 ml, placebo injection, biweekly subcutaneous abdominal injections for 26 weeks (core treatment period), after which placebo was randomized 1:1 to JY09 (1.2 mg) and JY09 (2.4 mg) continued subcutaneous abdominal injections biweekly for 28 weeks (extended treatment period).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HbA1c
Time Frame: Baseline, Week 26
|
Change in glycated hemoglobin (HbA1c) values relative to baseline after 26 weeks of treatment.
|
Baseline, Week 26
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The proportion of HbA1c <6.5% and <7%
Time Frame: Baseline, Week 26,Week 54
|
Proportion of subjects with HbA1c <7% and HbA1c <6.5% after 26 and 54 weeks of treatment.
|
Baseline, Week 26,Week 54
|
HbA1c
Time Frame: Baseline, Week 6,Week 10,Week 14,Week 20,Week 38,Week 54
|
Change in HbA1c relative to baseline after 6, 10, 14, 20, 38, and 54 weeks of treatment.
|
Baseline, Week 6,Week 10,Week 14,Week 20,Week 38,Week 54
|
fasting plasma glucose (FPG)
Time Frame: Baseline, Week 6,Week 10,Week 14,Week 20,Week 38,Week 54
|
Change in fasting plasma glucose (FPG) relative to baseline after 6, 10, 14, 20, 38, and 54 weeks of treatment.
|
Baseline, Week 6,Week 10,Week 14,Week 20,Week 38,Week 54
|
fasting insulin
Time Frame: Baseline, Week 14,Week 26,Week 54
|
Change in fasting insulin relative to baseline after 14, 26, and 54 weeks of treatment.
|
Baseline, Week 14,Week 26,Week 54
|
Homeostatic Model Assessment of Insulin Resistance(HOMA-IR)
Time Frame: Baseline,Week 26,Week 54
|
Change in HOMA-IR relative to baseline after 26 and 54 weeks of treatment.
|
Baseline,Week 26,Week 54
|
Health Survey Short Form (SF-36)
Time Frame: Baseline,Week 26,Week 54
|
Value of change in Health Survey Short Form (SF-36) scores relative to baseline after 26 and 54 weeks of treatment.
|
Baseline,Week 26,Week 54
|
blood pressure
Time Frame: Baseline,Week 26,Week 54
|
Change in blood pressure (sitting) relative to baseline after 26 and 54 weeks of treatment.
|
Baseline,Week 26,Week 54
|
Collaborators and Investigators
Investigators
- Principal Investigator: Linong Ji, Doctor, Peking University People's Hospital
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- DFBT-JY09-DM-301
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
Diabetes Foundation, IndiaNational Diabetes Obesity and Cholesterol FoundationRecruitingType 2 Diabetes Mellitus With ComplicationIndia
Clinical Trials on Exendin-4 Fc fusion protein injection
-
Beijing Dongfang Biotech Co., Ltd.Not yet recruiting
-
Beijing VDJBio Co., LTD.Recruiting
-
Bioverativ Therapeutics Inc.Swedish Orphan BiovitrumTerminatedHemophilia A | Hemophilia BUnited States
-
Zhejiang Hisun Pharmaceutical Co. Ltd.UnknownRheumatoid Arthritis | Ankylosing Spondylitis
-
FBD Biologics LimitedRecruitingAdvanced Solid Tumor | Refractory Non-Hodgkin LymphomaTaiwan, United States
-
Zhengzhou Gensciences IncJiangsu Gensciences lnc.Completed
-
Bioverativ, a Sanofi companySwedish Orphan BiovitrumCompletedHemophilia BUnited States, Italy, Ireland, New Zealand, United Kingdom, Australia, Netherlands, Denmark, Poland, Sweden, France
-
Bioverativ Therapeutics Inc.Swedish Orphan BiovitrumCompletedSevere Hemophilia AUnited States, Australia, New Zealand
-
Bioverativ, a Sanofi companySwedish Orphan BiovitrumCompletedHemophilia AUnited States, France, Italy, Spain, Netherlands, United Kingdom, Ireland, New Zealand, Poland, Australia, Germany, Brazil, Sweden, Canada
-
Bioverativ Therapeutics Inc.CompletedSevere Hemophilia BUnited States, Italy, Belgium, Australia, Brazil, Hong Kong, India, Ireland, Japan, South Africa, United Kingdom, Netherlands, Sweden, Canada, Poland, China, France, Germany